Australia's most trusted
source of pharma news
Monday, 16 September 2024
Posted 9 February 2024 AM
He has steered the company and its blockbuster semaglutide franchise to dizzying heights so it's no surprise that Novo Nordisk CEO Lars Fruergaard Jorgensen took home a bumper pay packet for his performance in 2023.
The company's annual remuneration report reveals a hike of 13.5 per cent on his previous year's package with the boss of arguably one of the most sought after drugs in the world pocketing a cool AUD$15 million.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.